help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wolthers, T.
Right arrow Articles by Foegh, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wolthers, T.
Right arrow Articles by Foegh, M.

Journal of Clinical Endocrinology & Metabolism, Vol 78, 141-144, Copyright © 1994 by Endocrine Society

ARTICLES

Dose-dependent stimulation of insulin-like growth factor-binding protein-1 by lanreotide, a somatostatin analog

T Wolthers, T Grofte, A Flyvbjerg, J Frystyk, H Vilstrup, H Orskov and M Foegh
Institute of Experimental Clinical Research, University Hospital, Kommunehospitalet, Aarhus C, Denmark.

It was recently reported that octreotide, besides its many, almost obligatory, inhibitory actions, stimulates the release of insulin-like growth factor-binding protein-1. The present study sought to exclude the possibility that the inescapable preceding somatostatin analog- induced reduction in serum insulin participated in the observed effect. We, therefore, administered sc two clinically relevant doses (5 and 80 micrograms/kg) of lanreotide, another somatostatin octapeptide analog, which induced identical 60% initial suppressions of serum insulin. In spite of this, clear dose-dependent increases in insulin-like growth factor-binding protein-1 were observed, starting between 1-2 h after administration of lanreotide, and levels were still elevated several- fold 5 h after administration of 80 micrograms/kg lanreotide. In addition, we found that infusion of amino acids had no discernible effect on binding protein-1 release. The changes found in immunoreactive binding protein-1 were confirmed employing Western ligand blotting. The data indicate that the lanreotide-induced increase in binding protein-1 levels in serum is not due to the changes in circulating insulin. The magnitude and duration of the increase raise the possibility that the stimulation may have clinically relevant implications in somatostatin analog treatment.


This article has been cited by other articles:


Home page
 CirculationHome page
R. von Essen, R. Ostermaier, E. Grube, W. Maurer, U. Tebbe, R. Erbel, M. Roth, W. Oel, J. Brom, G. Weidinger, et al.
Effects of Octreotide Treatment on Restenosis After Coronary Angioplasty : Results of the VERAS Study
Circulation, September 2, 1997; 96(5): 1482 - 1487.
[Abstract] [Full Text]

Home page
 CirculationHome page
J. Frystyk, C. Skjærbæk, N. Alexander, H. Emanuelsson, H. Suryapranata, H. Beyer, M. Foegh, and H. Orskov
Lanreotide Reduces Serum Free and Total Insulin-Like Growth Factor-I After Angioplasty
Circulation, November 15, 1996; 94(10): 2465 - 2471.
[Abstract] [Full Text]

Home page
 Reproductive SciencesHome page
E. Carmina, F. Z. Stanczyk, R. S. Morris, P. D. K. Lee, G. Savjani, and R. A. Lobo
Altered Regulation of Insulin-Like Growth Factor Binding Protein-I in Patients With Polycystic Ovary Syndrome
Reproductive Sciences, November 1, 1995; 2(6): 743 - 747.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1994 by The Endocrine Society